Media Release – 21st November 2019

Mind Medicine Australia announces new appointment to Board of Directors

Mind Medicine Australia Chairman Peter Hunt AM today announced the appointment of the Hon Andrew Robb AO as a Non-Executive Director to the board of Mind Medicine Australia.

Welcoming Andrew to the Board, Peter noted the extensive public policy, political, business and mental health advocacy experience.

"Andrew brings a wealth of knowledge with his 40-year career in both government and business, but more importantly, Andrew has been a prominent and public figure in the fight to remove the stigma surrounding mental health."

In taking up his position as Director, Mr. Robb said: "Despite the prevalence and impacts of mental health conditions, so little is known. The science has not progressed in decades. I look forward to helping Peter Hunt and Tania de Jong raise awareness about psychedelic-assisted psychotherapy and ultimately ensure this form of treatment is available for all Australians."

Until his recent retirement from politics, Mr. Robb was Australia's Minister for Trade, Investment and Tourism. Mr. Robb is currently Chairman of the Robb Group, Board member of the Kidman cattle enterprise, Chair of Asialink and pharmacogenetics company, CNSDose.

In 2011, Mr. Robb published a memoir, “Black Dog Daze: Public Life, Private Demons” (Melbourne University Publishing), that explores the challenges of managing depression and a public career in politics.

About Mind Medicine Australia www.mindmedicineaustralia.org

Mind Medicine Australia is seeking to establish safe and effective psychedelic-assisted treatments for mental illness in Australia. As a registered charity (DGR-1 status), we are supporting clinical research and working towards regulatory-approved and evidence-based psychedelic-assisted therapies. We operate as a nexus between medical practitioners, academia, government, regulatory bodies, philanthropists, and other partners.

Mind Medicine Australia is focused specifically on the clinical application of medicinal psilocybin and medicinal MDMA for certain mental illnesses. We do not advocate for recreational use of psychedelics, MDMA, or any other prohibited substances, nor do we advocate for any changes to the law with respect to recreational use. Our focus is wholly clinical.